Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 67 | $517 | $419.42 | -$97.58 | -18.87% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 17,741 | $119,220 | $131,460.81 | $12,240.81 | 10.27% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 31 | $223.12 | $233.12 | $10 | 4.48% |
| NA Nizar Araji National Bank Of Canada /FI/ | 120 | $2,036.4 | $889.2 | -$1,147.2 | -56.33% |
 Point72 Asset Management LP Point72 Asset Management LP | 231,582 | $1.52M | $1.91M | $387,357.46 | 25.51% |
Arcturus Therapeutics Holdings Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| IZ Ilya Zubkov Freedom Broker | 7,120.87 | $48,200.69 | $108,166.02 | $59,965.33 | 124.41% |
Arcturus Therapeutics Holdings Inc. (ARCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arcturus Therapeutics Holdings Inc. ever had a stock split?
Arcturus Therapeutics Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joseph E. Payne CEO | NASDAQ (NMS) Exchange | 03969T109 CUSIP |
| US Country | 109 Employees | - Last Dividend | 16 Nov 2017 Last Split | 16 Apr 2020 IPO Date |
Overview
Arcturus Therapeutics Holdings Inc. is a pioneering company deeply involved in the late-stage clinical development of messenger RNA (mRNA) medicines and vaccines, concentrating its efforts on addressing infectious diseases and targeting liver and respiratory rare diseases. Leveraging innovative technology platforms such as LUNAR lipid-mediated delivery and STARR mRNA, Arcturus is at the forefront of crafting therapeutic solutions aimed at some of the most challenging health conditions. Since its inception in 2013, with its headquarters established in San Diego, California, the company has dedicated itself to advancing the field of mRNA-based therapeutics and vaccines.
Products and Services
Arcturus Therapeutics Holdings Inc. has developed a diverse pipeline of mRNA-based therapeutic candidates and vaccines tailored for a variety of diseases, which includes:
- ARCT-810 (LUNAR-OTC): A groundbreaking mRNA-based therapeutic candidate, currently in Phase 2 clinical trials, designed to treat ornithine transcarbamylase deficiency. This condition is a rare genetic disorder that affects the liver's ability to break down ammonia, potentially leading to life-threatening complications.
- ARCT-154 (LUNAR-COV19): An advanced mRNA vaccine candidate positioned in the Phase 3 arm of a comprehensive Phase 1/2/3 study in Vietnam. It aims to offer protection against COVID-19, showcasing the company’s commitment to addressing ongoing global health crises.
- ARCT-032 (LUNAR-CF): A pioneering mRNA therapeutic candidate for cystic fibrosis, a debilitating genetic disorder that affects the lungs and digestive system. This candidate represents a potential breakthrough in treating this challenging condition, emphasizing the company’s focus on respiratory rare diseases.
- ARCT-2301 for bivalent: ancestral/omicron: Currently in Phase 3, this innovative solution reflects Arcturus's capability to respond to the evolving landscape of infectious diseases by targeting both the ancestral and omicron variants of COVID-19.
- ARCT-2303 for monovalent: Another candidate in Phase 3, dedicated to offering monovalent protection against COVID-19, underlining the company’s versatile approach to vaccine development.
- ARCT-2138 for quadrivalent: A quadrivalent solution in Phase 1, illustrating the company's forward-thinking in creating comprehensive vaccine options that provide broader protection against multiple variants or diseases.
- LUNAR-FLU: A pre-clinical trial candidate, this influenza vaccine highlights Arcturus’s expansion into other respiratory illnesses, aiming to leverage its mRNA and delivery technologies to combat seasonal and pandemic flu threats.
